Aurobindo Pharma Limited FII & DII Activity

Today's Institutional Flow

On September 4 2026, foreign institutional investors (FIIs) posted a net cash outflow of ₹‑3,111.94 Cr, while domestic institutional investors (DIIs) injected a net ₹ 8,930.12 Cr into the market. The contrasting polarity underscores a clear risk‑off stance among overseas participants, juxtaposed with robust buying by domestic entities. The aggregate net cash flow for the day therefore swings positive, driven primarily by the DII’s sizeable purchase activity.

Trend vs 5‑Day Average

The FII cash outflow of ₹‑3,111.94 Cr is less aggressive than their 5‑day average net outflow of ₹‑3,333.81 Cr, indicating a modest easing of foreign selling pressure. Conversely, the DII’s net inflow of ₹ 8,930.12 Cr exceeds the 5‑day average DII inflow of ₹ 4,430.43 Cr, suggesting amplified domestic buying momentum relative to the preceding week.

F&O Positioning Data

FIIs hold a net long position of ₹ 374,795 Cr in futures and options contracts, reflecting a bullish stance in the derivatives market. Their index futures exposure retains a long‑to‑short ratio of 1.2, signaling a slight net long bias across equity index contracts.

Healthcare Sector Flow

The healthcare segment, to which Aurobindo Pharma Limited belongs, has been experiencing a net inflow from domestic institutions while foreign investors have been net sellers over the past week, reinforcing the sector’s divergent institutional sentiment.